Schistosomiasis vaccines

Human Vaccines

Volumn 7, Issue 11, 2011, Pages 1192-1197

  Siddiqui, Afzal A ^a   Siddiqui, Bilal A ^b   Ganley Leal, Lisa ^c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calpain; Neglected tropical disease (NTD); Protective immunity; Schistosomiasis; Sm p80; Vaccines

Indexed keywords

ANTISCHISTOSOMAL AGENT; PRAZIQUANTEL; PROTECTIVE AGENT; SCHISTOSOMA HEMATOBIUM 28 GST ANTIGEN; SCHISTOSOMA MANSONI 14 ANTIGEN; SCHISTOSOMA MANSONI P80 VACCINE; SCHISTOSOMA VACCINE; TETRASPANIN; UNCLASSIFIED DRUG;

CONTROL STRATEGY; DRUG COST; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SYNTHESIS; DRUG TREATMENT FAILURE; EGG PRODUCTION; HUMAN; INFECTION CONTROL; NONHUMAN; PARASITE TRANSMISSION; PROTECTION; PROTEIN TARGETING; REVIEW; SCHISTOSOMA; SCHISTOSOMIASIS; SCHISTOSOMIASIS HAEMATOBIA; SCHISTOSOMIASIS JAPONICA; SCHISTOSOMIASIS MANSONI; VACCINATION; VACCINE FAILURE;

EID: 81855174806     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.11.17017     Document Type: Review

References (73)

1. Gryseels B, Polman K, Clerinx J, Kestens L. Human schistosomiasis. Lancet 2006; 368:1106-18; PMID:16997665; DOI:10.1016/S0140-6736(06)69440-3.
2. Hotez PJ, Molyneux DH, Fenwick A, Kumaresan J, Sachs SE, Sachs JD, et al. Control of neglected tropical diseases. N Engl J Med 2007; 357:1018-27; PMID:17804846; DOI:10.1056/NEJMra064142.
3. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis and estimates of people at risk. Lancet Infect Dis 2006; 6:411-25; PMID:16790382; DOI:10.1016/S1473-3099(06)70521-7.
4. Gray DJ, McManus DP, Li Y, Williams GM, Bergquist R, Ross AG. Schistosomiasis elimination: lessons from the past guide the future. Lancet Infect Dis 2010; 10:733-6; PMID:20705513; DOI:10.1016/S1473-3099(10)70099-2.
5. Karanja DM, Hightower AW, Colley DG, Mwinzi PN, Galil K, Andove J, et al. Resistance to reinfection with Schistosoma mansoni in occupationally exposed adults and effect of HIV-1 co-infection on susceptibility to schistosomiasis: a longitudinal study. Lancet 2002; 360:592-6; PMID:12241930; DOI:10.1016/S0140- 6736(02)09781-7.
6. King CH. Parasites and poverty: the case of schistosomiasis. Acta Trop 2010; 113:95-104; PMID:19962954; DOI:10.1016/j.actatropica.2009.11.012.
7. Hotez PJ, Bundy DAP, Beegle K, Brooker S, Drake L, de SN, et al. Helminth Infections: Soil-transmitted Helminth Infections and Schistosomiasis 2006.
8. Hotez PJ, Engels D, Fenwick A, Savioli L. Africa is desperate for praziquantel. Lancet 2010; 376:496-8; PMID:20709217; DOI:10.1016/S0140-6736(10) 60879-3.
9. Black CL, Muok EM, Mwinzi PN, Carter JM, Karanja DM, Secor WE, et al. Increases in levels of schistosomespecific immunoglobulin E and CD23(+) B cells in a cohort of Kenyan children undergoing repeated treatment and reinfection with Schistosoma mansoni. J Infect Dis 2010; 202:399-405; PMID:20560767; DOI:10.1086/653828.
10. Bergquist R, Utzinger J, McManus DP. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl Trop Dis 2008; 2:244; PMID:18575619; DOI:10.1371/journal.pntd.0000244.
11. Doenhoff MJ, Hagan P, Cioli D, Southgate V, Pica- Mattoccia L, Botros S, et al. Praziquantel: its use in control of schistosomiasis in sub-Saharan Africa and current research needs. Parasitology 2009; 136:1825-35; PMID:19281637; DOI:10.1017/ S0031182009000493.
12. McManus DP, Loukas A. Current status of vaccines for schistosomiasis. Clin Microbiol Rev 2008; 21:225-42; PMID:18202444; DOI:10.1128/CMR.00046-07.
13. Berriman M, Haas BJ, LoVerde PT, Wilson RA, Dillon GP, Cerqueira GC, et al. The genome of the blood fluke Schistosoma mansoni. Nature 2009; 460:352-8; PMID:19606141; DOI:10.1038/nature08160.
14. James CE, Hudson AL, Davey MW. An update on P-glycoprotein and drug resistance in Schistosoma mansoni. Trends Parasitol 2009; 25:538-9; PMID:19850522; DOI:10.1016/j.pt.2009.09.007.
15. Bergquist NR, Leonardo LR, Mitchell GF. Vaccinelinked chemotherapy: can schistosomiasis control benefit from an integrated approach? Trends Parasitol 2005; 21:112-7; PMID:15734657; DOI:10.1016/j. pt.2005.01.001.
16. Siddiqui AA, Ahmad G, Damian RT, Kennedy RC. Experimental vaccines in animal models for schistosomiasis. Parasitol Res 2008; 102:825-33; PMID:18259777; DOI:10.1007/s00436-008-0887-6.
17. Hagan P, Sharaf O. Schistosomiasis vaccines. Expert Opin Biol Ther 2003; 3:1271-8; PMID:14640953; DOI:10.1517/14712598.3.8.1271.
18. Lebens M, Sun JB, Czerkinsky C, Holmgren J. Current status and future prospects for a vaccine against schistosomiasis. Expert Rev Vaccines 2004; 3:315-28; PMID:15176948; DOI:10.1586/14760584.3.3.315.
19. Rappuoli R, Aderem A. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 2011; 473:463-9; PMID:21614073; DOI:10.1038/ nature10124.
20. Smythies LE, Betts C, Coulson PS, Dowling MA, Wilson RA. Kinetics and mechanism of effector focus formation in the lungs of mice vaccinated with irradiated cercariae of Schistosoma mansoni. Parasite Immunol 1996; 18:359-69; PMID:9229389; DOI:10.1046/j.1365-3024.1996.d01-115.x.
21. Cutts L, Wilson RA. Elimination of a primary schistosome infection from rats coincides with elevated IgE titres and mast cell degranulation. Parasite Immunol 1997; 19:91-102; PMID:9076811; DOI:10.1046/j.1365-3024.1997.d01-184.x.
22. Wilson RA, Langermans JA, Van Dam GJ, Vervenne RA, Hall SL, Borges WC, et al. Elimination of Schistosoma mansoni Adult Worms by Rhesus Macaques: Basis for a Therapeutic Vaccine? PLoS Negl Trop Dis 2008; 2:290; PMID:18820739; DOI:10.1371/journal. pntd.0000290.
23. Hagan P, Blumenthal UJ, Dunn D, Simpson AJ, Wilkins HA. Human IgE, IgG4 and resistance to reinfection with Schistosoma haematobium. Nature 1991; 349:243-5; PMID:1898985; DOI:10.1038/349243a0.
24. Hagan P. Reinfection, exposure and immunity in human schistosomiasis. Parasitol Today 1992; 8:12-6; PMID:15463518; DOI:10.1016/0169-4758(92)90303-J.
25. Meeusen EN, Walker J, Peters A, Pastoret PP, Jungersen G. Current status of veterinary vaccines. Clin Microbiol Rev 2007; 20:489-510; PMID:17630337; DOI:10.1128/CMR.00005-07.
26. Olson CL, Acosta LP, Hochberg NS, Olveda RM, Jiz M, McGarvey ST, et al. Anemia of inflammation is related to cognitive impairment among children in Leyte, the Philippines. PLoS Negl Trop Dis 2009; 3:533; PMID:19847303; DOI:10.1371/journal. pntd.0000533.
27. Bergquist R. Prospects of vaccination against schistosomiasis. Scand J Infect Dis Suppl 1990; 76:60-71; PMID:2102021.
28. Todd CW, Colley DG. Practical and ethical issues in the development of a vaccine against Schistosomiasis mansoni. Am J Trop Med Hyg 2002; 66:348-58; PMID:12164288.
29. Bickle QD. Radiation-attenuated schistosome vaccination-a brief historical perspective. Parasitology 2009; 136:1621-32; PMID:19327194; DOI:10.1017/ S0031182009005848.
30. Hewitson JP, Hamblin PA, Mountford AP. Immunity induced by the radiation-attenuated schistosome vaccine. Parasite Immunol 2005; 27:271-80; PMID:16138848; DOI:10.1111/j.1365-3024.2005.00764.x.
31. Kumar P, Ramaswamy K. Vaccination with irradiated cercariae of Schistosoma mansoni preferentially induced the accumulation of interferon-gamma producing T cells in the skin and skin draining lymph nodes of mice. Parasitol Int 1999; 48:109-19; PMID:11269272; DOI:10.1016/S1383-5769(99)00008-2.
32. Jankovic D, Wynn TA, Kullberg MC, Hieny S, Caspar P, James S, et al. Optimal vaccination against Schistosoma mansoni requires the induction of both B cell- and IFNgamma-dependent effector mechanisms. J Immunol 1999; 162:345-51; PMID:9886405.
33. Dunne DW, Butterworth AE, Fulford AJ, Kariuki HC, Langley JG, Ouma JH, et al. Immunity after treatment of human schistosomiasis: association between IgE antibodies to adult worm antigens and resistance to reinfection. Eur J Immunol 1992; 22:1483-94; PMID:1601036; DOI:10.1002/eji.1830220622.
34. Dunne DW, Butterworth AE, Fulford AJ, Ouma JH, Sturrock RF. Human IgE responses to Schistosoma mansoni and resistance to reinfection. Mem Inst Oswaldo Cruz 1992; 87:99-103; PMID:1343933; DOI:10.1590/S0074-02761992000800014.
35. Pinot de Moria A, Fulford AJ, Kabatereine NB, Ouma JH, Booth M, Dunne DW. Analysis of complex patterns of human exposure and immunity to Schistosomiasis mansoni: the influence of age, sex, ethnicity and IgE. PLoS Negl Trop Dis 2010; 4:820; PMID:20856909; DOI:10.1371/journal.pntd.0000820.
36. Kurtis JD, Friedman JF, Leenstra T, Langdon GC, Wu HW, Manalo DL, et al. Pubertal development predicts resistance to infection and reinfection with Schistosoma japonicum. Clin Infect Dis 2006; 42:1692-8; PMID:16705573; DOI:10.1086/504326.
37. Olds GR. New insights into the observed age-specific resistance to reinfection with Schistosoma japonicum. Clin Infect Dis 2006; 42:1699-701; PMID:16705574; DOI:10.1086/504331.
38. Butterworth AE, Dunne DW, Fulford AJ, Thorne KJ, Gachuhi K, Ouma JH, et al. Human immunity to Schistosoma mansoni: observations on mechanisms and implications for control. Immunol Invest 1992; 21:391-407; PMID:1428017; DOI:10.3109/08820139209069381.
39. Ganley-Leal LM, Mwinzi PN, Cetre-Sossah CB, Andove J, Hightower AW, Karanja DM, et al. Correlation between eosinophils and protection against reinfection with Schistosoma mansoni and the effect of human immunodeficiency virus type 1 coinfection in humans. Infect Immun 2006; 74:2169-76; PMID:16552047; DOI:10.1128/IAI.74.4.2169- 76.2006.
40. Leenstra T, Acosta LP, Wu HW, Langdon GC, Solomon JS, Manalo DL, et al. T-helper-2 cytokine responses to Sj97 predict resistance to reinfection with Schistosoma japonicum. Infect Immun 2006; 74:370-81; PMID:16368992; DOI:10.1128/IAI.74.1.370-81.2006.
41. + B cell subset correlates with the development of resistance to Schistosoma mansoni reinfection in occupationally exposed adults who have undergone multiple treatments. J Infect Dis 2009; 199:272-9; PMID:19072134; DOI:10.1086/595792.
42. Bergquist R, Utzinger J, Chollet J, Shu-Hua X, Weiss NA, Tanner M. Triggering of high-level resistance against Schistosoma mansoni reinfection by artemether in the mouse model. Am J Trop Med Hyg 2004; 71:774-7; PMID:15642970.
43. Bethony JM, Cole RN, Guo X, Kamhawi S, Lightowlers MW, Loukas A, et al. Vaccines to combat the neglected tropical diseases. Immunol Rev 2011; 239:237-70; PMID:21198676; DOI:10.1111/j.1600-065X.2010.00976.x.
44. Capron A, Dessaint JP, Capron M, Pierce RJ. Vaccine strategies against schistosomiasis. Mem Inst Oswaldo Cruz 1992; 87:19-27; PMID:1343894; DOI:10.1590/ S0074-02761992000800003
45. Hagan P. Schistosomiasis-a rich vein of research. Parasitology 2009; 136:1611-9; PMID:19691867; DOI:10.1017/S003118200999093X.
46. Capron A, Riveau G, Capron M, Trottein F. Schistosomes: the road from host-parasite interactions to vaccines in clinical trials. Trends Parasitol 2005; 21:143-9; PMID:15734662; DOI:10.1016/j.pt.2005.01.003.
47. Tendler M, Vilar MM, Brito CA, Freire NM, Katz N, Simpson A. Vaccination against schistosomiasis and fascioliasis with the new recombinant antigen Sm14: potential basis of a multi-valent antihelminth vaccine? Mem Inst Oswaldo Cruz 1995; 90:255-6; PMID:8531667; DOI:10.1590/S0074-02761995000200022.
48. Tendler M, Simpson AJ. The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. Acta Trop 2008; 108:263-6; PMID:18834847; DOI:10.1016/j.actatropica.2008.09.002.
49. Siddiqui AA, Zhou Y, Podesta RB, Karcz SR, Tognon CE, Strejan GH, et al. Characterization of Ca(2+)- dependent neutral protease (calpain) from human blood flukes, Schistosoma mansoni. Biochim Biophys Acta 1993; 1181:37-44; PMID:8457603.
50. Ahmad G, Zhang W, Torben W, Haskins C, Diggs S, Noor Z, et al. Prime-boost and recombinant protein vaccination strategies using Sm-p80 protects against Schistosoma mansoni infection in the mouse model to levels previously attainable only by the irradiated cercarial vaccine. Parasitol Res 2009; 105:1767-77; PMID:19809833; DOI:10.1007/s00436-009-1646-z.
51. Ahmad G, Torben W, Zhang W, Wyatt M, Siddiqui AA. Sm-p80-based DNA vaccine formulation induces potent protective immunity against Schistosoma mansoni. Parasite Immunol 2009; 31:156-61; PMID:19222788; DOI:10.1111/j.1365- 3024.2008.01091.x.
52. Ahmad G, Zhang W, Torben W, Damian RT, Wolf RF, White GL, et al. Protective and antifecundity effects of Sm-p80-based DNA vaccine formulation against Schistosoma mansoni in a nonhuman primate model. Vaccine 2009; 27:2830-7; PMID:19366570; DOI:10.1016/j.vaccine.2009.02.096.
53. Ahmad G, Zhang W, Torben W, Noor Z, Siddiqui AA. Protective effects of Sm-p80 in the presence of resiquimod as an adjuvant against challenge infection with Schistosoma mansoni in mice. Int J Infect Dis 2010; 14:781-7; PMID:20630783; DOI:10.1016/j. ijid.2010.02.2266.
54. Ahmad G, Zhang W, Torben W, Ahrorov A, Damian RT, Wolf RF, et al. Preclinical Prophylactic Efficacy Testing of Sm-p80-Based Vaccine in a Nonhuman Primate Model of Schistosoma mansoni Infection and Immunoglobulin G and E Responses to Sm-p80 in Human Serum Samples From an Area Where Schistosomiasis Is Endemic J Infect Dis 2011; 204:1437-49; PMID: 21921206; DOI: 10.1093/ infdis/jir545.
55. Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, et al. Enhancement of Sm-p80 (large subunit of calpain) induced protective immunity against Schistosoma mansoni through co-delivery of interleukin-2 and interleukin-12 in a DNA vaccine formulation. Vaccine 2003; 21:2882-9; PMID:12798631; DOI:10.1016/S0264-410X(03)00159-2.
56. Siddiqui AA, Phillips T, Charest H, Podesta RB, Quinlin ML, Pinkston JR, et al. Induction of protective immunity against Schistosoma mansoni via DNA priming and boosting with the large subunit of calpain (Smp80): adjuvant effects of granulocyte-macrophage colony- stimulating factor and interleukin-4. Infect Immun 2003; 71:3844-51; PMID:12819068; DOI:10.1128/ IAI.71.7.3844-51.2003.
57. Siddiqui AA, Pinkston JR, Quinlin ML, Kavikondala V, Rewers-Felkins KA, Phillips T, et al. Characterization of protective immunity induced against Schistosoma mansoni via DNA priming with the large subunit of calpain (Sm-p80) in the presence of genetic adjuvants. Parasite 2005; 12:3-8; PMID:15828575.
58. Siddiqui AA, Pinkston JR, Quinlin ML, Saeed Q, White GL, Shearer MH, et al. Characterization of the immune response to DNA vaccination strategies for schistosomiasis candidate antigen, Sm-p80 in the baboon. Vaccine 2005; 23:1451-6; PMID:15670880; DOI:10.1016/j.vaccine.2004.09.018.
59. Torben W, Ahmad G, Zhang W, Siddiqui AA. Role of antibodies in Sm-p80-mediated protection against Schistosoma mansoni challenge infection in murine and nonhuman primate models. Vaccine 2011; 29:2262-71; PMID:21277404; DOI:10.1016/j.vaccine. 2011.01.040.
60. Zhang W, Ahmad G, Torben W, Noor Z, Le L, Damian RT, et al. Sm-p80-based DNA vaccine provides baboons with levels of protection against Schistosoma mansoni infection comparable to those achieved by the irradiated cercarial vaccine. J Infect Dis 2010; 201:1105-12; PMID:20187746; DOI:10.1086/651147.
61. Zhang W, Ahmad G, Torben W, Siddiqui AA. Sm-p80- based DNA vaccine made in a human use approved vector VR1020 protects against challenge infection with Schistosoma mansoni in mouse. Parasite Immunol 2010; 32:252-8; PMID:20398225; DOI:10.1111/ j.1365-3024.2009.01181.x.
62. Zhang W, Ahmad G, Torben W, Siddiqui AA. Schistosoma mansoni antigen Sm-p80: Prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum). Acta Trop 2011; 118:142-51; PMID:21334302; DOI:10.1016/j.actatropica.2011.01.010.
63. Ohta N, Kumagai T, Maruyama H, Yoshida A, He Y, Zhang R. Research on calpain of Schistosoma japonicum as a vaccine candidate. Parasitol Int 2004; 53:175-81; PMID:15081949; DOI:10.1016/j. parint.2004.01.007.
64. Zhang R, Yoshida A, Kumagai T, Kawaguchi H, Maruyama H, Suzuki T, et al. Vaccination with calpain induces a Th1-biased protective immune response against Schistosoma japonicum. Infect Immun 2001; 69:386-91; PMID:11119528; DOI:10.1128/ IAI.69.1.386-91.2001.
65. Hota-Mitchell S, Siddiqui AA, Dekaban GA, Smith J, Tognon C, Podesta RB. Protection against Schistosoma mansoni infection with a recombinant baculovirus-expressed subunit of calpain. Vaccine 1997; 15:1631-40; PMID:9364694; DOI:10.1016/S0264-410X(97)00081-9.
66. Hota-Mitchell S, Clarke MW, Podesta RB, Dekaban GA. Recombinant vaccinia viruses and gene gun vectors expressing the large subunit of Schistosoma mansoni calpain used in a murine immunization-challenge model. Vaccine 1999; 17:1338-54; PMID:10195769; DOI:10.1016/S0264-410X(98)00391-0.
67. Jankovic D, Aslund L, Oswald IP, Caspar P, Champion C, Pearce E, et al. Calpain is the target antigen of a Th1 clone that transfers protective immunity against Schistosoma mansoni. J Immunol 1996; 157:806-14; PMID:8752932.
68. El Ridi R, Tallima H. Schistosoma mansoni ex vivo lung-stage larvae excretory-secretory antigens as vaccine candidates against schistosomiasis. Vaccine 2009; 27:666-73; PMID:19056448; DOI:10.1016/j.vaccine. 2008.11.039.
69. El Ridi R, Tallima H, Mahana N, Dalton JP. Innate immunogenicity and in vitro protective potential of Schistosoma mansoni lung schistosomula excretorysecretory candidate vaccine antigens. Microbes Infect 2010; 12:700-9; PMID:20452455; DOI:10.1016/j. micinf.2010.04.012.
70. Osada Y, Kumagai T, Hato M, Suzuki T, El-Malky M, Asahi H, et al. Establishment of Schistosoma japonicum calpain-specific mouse T cell hybridomas and identification of a T cell epitope that stimulates IFNgamma production. Vaccine 2005; 23:2813-9; PMID:15780729; DOI:10.1016/j.vaccine.2004.10.042.
71. Tran MH, Pearson MS, Bethony JM, Smyth DJ, Jones MK, Duke M, et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006; 12:835-40; PMID:16783371; DOI:10.1038/nm1430.
72. Hotez PJ, Bethony JM, Diemert DJ, Pearson M, Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat Rev Microbiol 2010; 8:814-26; PMID:20948553; DOI:10.1038/nrmicro2438.
73. Zhang W, Li J, Duke M, Jones MK, Kuang L, Zhang J, et al. Inconsistent Protective Efficacy and Marked Polymorphism Limits the Value of Schistosoma japonicum Tetraspanin-2 as a Vaccine Target. PLoS Negl Trop Dis 2011; 5:1166; PMID:21655308; DOI:10.1371/ journal.pntd.0001166.